Related Experiment Videos
Lymphocytotoxins in leprosy
1Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian Journal of Leprosy
|April 1, 1989
Summary
Elevated lymphocytotoxic antibodies (LCAs) were found in leprosy patients before treatment. Multi-drug therapy (MDT) led to a significant reduction in LCA levels across all leprosy types.
Area of Science:
- Immunology
- Infectious Diseases
- Dermatology
Background:
- Leprosy is a chronic infectious disease caused by Mycobacterium leprae.
- Lymphocytotoxic antibodies (LCAs) are implicated in immune responses.
- Understanding immune markers in leprosy is crucial for treatment monitoring.
Purpose of the Study:
- To quantify lymphocytotoxic antibody (LCA) levels in leprosy patients.
- To assess the impact of multi-drug therapy (MDT) on LCA levels.
Main Methods:
- Serum samples from 60 leprosy patients (pre-MDT and post-treatment) and 17 healthy controls were analyzed.
- Lymphocytotoxic antibody (LCA) levels were quantified using immunoassay techniques.
Main Results:
- Pre-treatment sera from all leprosy spectrum patients (LL, BL, BT/TT) showed elevated LCA levels.
- Significant reduction in LCA levels was observed in all patient groups following MDT.
Conclusions:
- Elevated LCA levels are associated with active leprosy.
- MDT is effective in reducing LCA production, indicating immune modulation.